RxDoctor Payments Data

Jill Nichols, APRN

Women's Health · Maumee, OHNPI 1417688144

Payments from drug & device makers

What this record shows

The money is spread across several categories — travel and lodging (49.7%), food and beverage and education — rather than concentrated in one kind of arrangement. 12 manufacturers reported payments, led by Axonics, Inc. at 43.3% of the total. Reporting peaked in 2023 at $1,695 and has fallen 96.2% since, to $65 in 2025. Among women's health clinicians in OH with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$2,975in general payments, 2019–2025

Across 48 payments — averaging $61.99 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Axonics, Inc.$1K
  • Medtronic$832
  • Astellas Pharma US Inc$403
  • Sumitomo Pharma America, Inc.$120
  • Bayer$88
  • Coloplast$56
  • plus $189 from 6 others

What the payments were for

  • Travel & lodging$1,47950%
  • Food & beverage$1,39747%
  • Education$993%

General payments by program year

22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,975 in reported general payments places this provider in the 90th percentile of 333 women's health providers in Ohio.

See all women's health providers in Ohio

Medicare billing

Part B allowed, 2024
$28,750
Medicare patients
208
Services billed
618

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron17$14,216
Estradiol187$13,777
Clobetasol Propionate58$2,102
Methenamine Hippurate24$995
Trospium Chloride21$919
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst77$887
Estradiol (Once Weekly)Estradiol16$797
Oxybutynin Chloride ErOxybutynin Chloride30$705
Metronidazole11$368
Nystatin-TriamcinoloneNystatin/Triamcinolone Acet14$294
Terconazole14$279
Cephalexin36$187
Oxybutynin Chloride11$155
Nystatin11$145
Alendronate Sodium11$87

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Astellas Pharma US IncMyrbetriq$403$14,21617 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 333 women's health providers in Ohio.

Other women's health in Maumee

See the full list for Ohio

Where these figures come from

Is this you, or does something look wrong? →